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Abstract: Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct 
reprogramming to desired cell types are powerful and new in vitro methods for the study  
of human disease, cell replacement therapy, and drug development. Both methods to 
reprogram cells are unconstrained by the ethical and social questions raised by embryonic 
stem cells. iPSC technology promises to enable personalized autologous cell therapy and 
has the potential to revolutionize cell replacement therapy and regenerative medicine. 
Potential applications of iPSC technology are rapidly increasing in ambition from discrete 
cell replacement applications to the iPSC assisted bioengineering of body organs for 
personalized autologous body organ transplant. Recent work has demonstrated that  
the generation of organs from iPSCs is a future possibility. The development of  
embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an 
early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac 
muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and 
functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and 
unique possibility to make body organs for transplantation removing the need for organ 
donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming 
the lead cell type for research into cell replacement therapy and body organ transplantation 
strategies in humans, it is not known whether (1) such transplants will stimulate host 
immune responses; and (2) whether this technology will be capable of the bioengineering 
of a complete and fully functional human organ. This review will not focus on 
reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on 
the latest developments in direct reprogramming of cells, the bioengineering of body 
organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells 
and tissues. 
Keywords: direct cell reprogramming; iPSC; autologous; immune response;  
organ bioengineering 
 
1. Direct Reprogramming 
Transdifferentiation, direct reprogramming or direct lineage reprogramming are the three different 
terms used for describing when the overexpression of certain factors makes a fully differentiated cell 
change its transcriptional and protein profile to directly convert it from one cell type into another 
without intermediate progenitor stages [1]. The historical origin of cell transdifferentiation has been 
elegantly reviewed before, clearly setting the stage for the future development and advancement of  
the field [2]. Many cell types have been made using direct reprogramming methodology as  
described below.  
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1.1. Myocytes and Cardiomyocytes 
The first report of direct reprogramming or transdifferentiation was that describing the conversion 
of fibroblasts, chondrocytes, and retinal epithelium into skeletal muscle by the transfection of the 
transcription factor MyoD [3]. The transdifferentiation into cardiomyocytes has not proved so simple 
as a master regulator gene for cardiomyocytes, similar to MyoD for skeletal muscle determination, has 
not been found. The group of Srivastava designed a screening strategy in which a group of  
14 candidate genes were tested in different combinations for the cardiomyocyte induction capacity [4]. 
After fine-tuning to find the best combination with the minimal number of genes, three factors, Gata4, 
Mef2c, and Tbx5, were identified that together induce direct reprogramming of source cells into 
cardiomyocytes. The direct reprogramming was successful from both dermal and cardiac fibroblasts 
and the resulting cardiomyocytes had features similar to neonatal cardiomyocytes including 
contractility. This strategy has several advantages compared to deriving cardiomyocytes from iPSCs, 
including a greater efficiency and speed in cardiomyocyte generation. 
1.2. Central Nervous Systems Cells 
The demonstration of in vitro direct reprogramming to neurons was first reported in 2002 when the 
conversion of astrocytes into neurons, by over-expression of Pax6 was described [5]. Because 
astrocytes share a common cell lineage to neurons, they require minimal manipulation to directly 
reprogram them to neurons and may not be the most feasible source of starting cells for 
transdifferentiation. More accessible cell types for direct reprogramming to neurons include;  
(i) fibroblasts by direct reprogrammed using Brn2, Ascl1, and Myt1l (BAM) [6]; (ii) hepatocytes using 
also BAM [7]; (iii) pericytes using Sox2 and Mash1 [8]; and cord blood using Sox2 and c-Myc [9]. 
Furthermore, fibroblasts can be directly lineage-reprogrammed into spinal motor neurons using 
Ascl1, Brn2, Myt1l, Lhx3, Hb9, Isl1, and Ngn2 [10]. Of particular interest is the ability to convert one 
neuronal subtype into another, namely embryonic and early postnatal callosal projection neurons into 
corticofugal projection neurons by overexpression of Fezf2 [11], indicating that there is a period after 
post-mitotic development when neurons can change their subtype. The demonstration that this is a 
stable conversion, at least during this post-mitotic period, remains to be done. 
Current methodologies employed in direct reprogramming carry a number of concerns when 
considered for clinical application. Formerly, all transdifferentiation strategies had been achieved 
using doxycycline-inducible lentiviral vectors. Fears of genotoxic integration and tumorigenicity 
associated with this method have been voiced. Testing of new non-viral methods for converting 
fibroblasts into neurons, by using plasmids as a gene carriers coding for BAM [12], by microRNA 
mediated conversion [13] and by using chemical compounds alone [14], have all been tried. These 
methods begin to pave the way for future clinical application and further work in this direction  
is warranted. 
To date, it has been shown in vitro that neurons made from either mouse or human cells by direct 
reprogramming methods are electrophysiologically active, form synapses in vitro and express markers 
of post-mitotic neurons. There exists evidence of induced-dopaminergic neurons partially integrating 
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with local neuronal circuitry after ectopic transplantation in mouse striatum, suggesting that direct 
reprogramming methods can make functional neurons that integrate successfully [15]. 
The challenge remains to demonstrate direct reprogramming in vivo to generate human neurons,  
as been demonstrated in mice, and, thus, circumvent the need for cell transplants [11,16,17]. 
Moreover, future work to achieve the production of different classes of neurons, that are specifically 
lost in distinct neurodegenerative disorders, is warranted. 
1.3. Immune B Cells into Macrophages and Treatment of Cancer 
A leading laboratory in the field of direct reprogramming of cells, has transdifferentiated a B 
lymphocyte cell line into macrophage-like cells at 100% efficiency, within two to three days, using an 
estradiol-inducible form of C/EBPalpha [2,18]. They demonstrated that the reprogrammed cells  
are larger, contain altered organelle and cytoskeletal structures, are phagocytic, and exhibit an 
inflammatory response. They conclude that the robustness and speed of their system make it a versatile 
tool to study biochemical and biological aspects of lineage reprogramming [18]. Interestingly, the 
same group has taken this finding further and demonstrated transdifferentiation of leukemia cell lines 
into macrophages, thus, impairing their tumorigenicity [19]. This work leads to the exciting idea of 
using cellular transdifferentiation as a method to treat cancer [19]. 
1.4. Hepatocytes and Pancreatic β-Cells 
Hepatocytes and pancreatic islet β-cells are two endoderm-derived cell types that are the subject of 
much attention due to their indispensable physiological functions and their association with various 
diseases. The adult β cells have very limited regenerative ability, which is insufficient to compensate 
for cell loss and is thus the cause of many diseases, including diabetes. For this reason, there has been 
a large effort to find new sources of β cells and other pancreatic cells. Until recently, efficient treatments 
for restoring the cellular functions of these cell types were unknown. Clinical studies have now 
demonstrated that cell transplantation-based therapy can support and restore functions of failed liver 
and pancreatic islets. Recent advances in hepatocyte and β cell transdifferentiation have provided 
valuable insights into how to regenerate and restore the normal function of the liver and the  
pancreas [20]. 
It has been reported that mouse embryonic and adult fibroblasts can be directly reprogrammed  
into functional hepatocyte-like cells using a combination of endodermal and hepatic transcription 
factors [21,22]. In both reports, hepatocyte-like cells exhibited typical hepatocyte morphology, gene 
expression and protein secretions. These cells may resemble an immature stage of hepatocyte 
differentiation. However, similar human hepatocyte-like cells have yet to be generated. Mesenchymal 
stem cells (MSC) are an alternative source of hepatic cells. The hepatocyte-like cells transdifferentiated 
from MSC can engraft into the parenchyma of the liver and at least partially restore liver functions in 
injury models in vivo [23]. Melton and his colleagues reported that re-activation of three transcription 
factors (Ngn3, Pdx1, and Mafa) in vivo was able to reprogram pancreatic exocrine cells into endocrine 
β cells in adult mice. They utilized a cell tracking system and demonstrated that overexpression of the 
three key pancreatic factors converted acinar cells to insulin-producing β cells. Moreover, these β cells 
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rescued mice from streptozotocin-induced diabetes, demonstrating a clear functional capacity of the 
cells [24]. 
Another source of new pancreatic cells is the inter-endocrine transition in pancreatic islets. Recent 
work has demonstrated that new β cells arose from healthy α cells in islets through transdifferentiation, 
which is induced by fatal β-cells ablation, as in diabetes [25]. Their results argue that a deep lesion 
(total or near-total β-cell ablation) causes the release of some form of signal that allows prolonged  
and substantial β-cell regeneration. Such inter-endocrine spontaneous adult cell conversion could be 
harnessed towards methods of producing β-cells for diabetes therapies, either in differentiation settings 
in vitro or induced regeneration [25]. 
As liver and pancreas arise from the same bi-potential precursors in the anterior endoderm,  
it is reasonable to speculate that two closely related tissues may be inter-convertible. For example,  
the glucocorticoid dexamethasone can efficiently induce rat pancreatic exocrine cells into  
hepatocytes [26], and there have been reports of hepatocyte transdifferentiation of hepatocytes into 
pancreatic β cells involving several key pancreatic factors [27,28]. These encouraging recent  
advance in liver and pancreatic cell transdifferentiation should promote continued development of cell 
replacement techniques for the future treatment of many liver and pancreas related diseases. 
1.5. Retinal Pigment Epithelium 
It has recently been described the conversion of human foreskin fibroblast into retinal pigment 
epithelium (RPE)-like cells by defined factors [29]. They developed an RPE-specific Best1::GFP 
reporter, which could faithfully represent human RPE lineage commitment during human embryonic 
stem cell differentiation. Using this reporter system, they showed that a defined set of transcription 
factors can reprogram human fibroblasts into Best1:GFP+ve colonies. They demonstrated that  
these Best1:GFP+ve cells formed pigmented monolayer epithelium exhibiting molecular features of 
RPE lineage. 
In the initial experiment, six RPE developmental transcription factors; Rax, Crx, Pax6, Mitf, Otx2, 
and Nrl were used [29]. Despite transfection of these factors through retroviruses, pGZ-BEST1-GFP 
through lentivirus and culturing on Matrigel-coated plates and in hESC culture medium to prime RPE 
lineage conversion, there was no morphological change and no Best1:GFP+ve cells. In the next 
experiment, epigenetic “plasticity” was increased with the addition of cMyc and Klf4 factors. The 
efficiency of RPE induction was altered by removal of certain combination of the six transcription 
factors. It was found that cMyc, Mitf, Otx2, Rax, and Crx were critical for reprogramming of human 
fibroblasts into Best1::GFP+ cells, while Klf4, Nrl, and Pax6, individually, were not as important and 
could potentially be omitted or replaced by other factors without major impact of induced RPE 
phenotype at day 35 post-transduction [29]. In addition, they observed further maturation of the 
induced RPE-like cells when they were maintained in medium containing retinoic acid and sonic 
hedgehog after day 21 [29]. This offers hope that there may be a safer combination of small molecules 
and transcription factors that can be used to induce RPE lineage from somatic cells for therapeutic 
application. However, the compulsory requirement of the cMyc oncogene and Klf4 to the transcription 
factor cocktail limits the clinical utility of this approach.  
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1.6. In Vivo Transdifferentiation 
In vivo direct reprogramming strategies involve cell transdifferentiation conducted not in vitro but 
in an adult organ of a living organism. One of the first examples of in vivo direct reprogramming 
(transdifferentiation) was in mice by targeting differentiated pancreatic exocrine cells and making cells 
that closely-resembled β cells by the expression of Ngn3, Pdx1, and Mafa [24]. The first insulin 
positive cells appeared as early as day three after gene induction, however, the induced β-cells did not 
organize into islet structures but remained as single cells or small clusters. More recently, hESCs were 
differentiated in vitro into pancreatic progenitors that were engrafted into mice, they matured in vivo 
into insulin producing pancreatic endocrine cells and achieved normoglycemia 30 weeks after 
transplantation [30]. The field of in vivo direct reprogramming offers advantages over in vitro 
transdifferentiation prior to delivery of cells, however, this technology still requires a lot of work to 
make functionally safe cells. As an alternative approach to in vivo direct reprogramming, the 
bioengineering of organs from iPSCs may become an easier and quicker approach towards future 
tissue regeneration strategies. 
2. iPSCs and Bioengineering Tissues 
There have been many attempts to bioengineer different organs from iPSCs such as brain, liver, 
heart, and other tissues listed below. In general, the successful creation of tissues and organs from 
iPSCs requires: 
1. An appropriate mixture of cells to recapitulate cell-cell interaction during organ development. 
This can be achieved either by differentiating the cells to early progenitors or by mixing them 
with other cell types or tissues. 
2. Providing a 3D scaffold or giving the right conditions for assembly in 3D. 
3. Providing the right extracellular matrix that resembles that of embryonic organogenesis. 
2.1. Heart 
The ability to generate functional cardiac tissue by in vitro tissue engineering with donor 
cardiomyocytes has been known for more than ten years [31–34] but more recent developments 
include ex vivo [35] and in vivo [36] methods, which also provide the vascular and fibrous elements of 
cardiac tissue. Cell sheet techniques allowed for iPSC-derived cardiomyocytes to be delivered to the 
porcine heart demonstrating acute benefits [37] and contractile and vascularized human cardiac 
organoids have also been created from iPSCs [38,39], which provide longer-term survival and 
contractility. However the ability to create whole functional hearts by means of tissue bioengineering 
has proven elusive. The closest result to this complex whole organ bioengineering task has been 
engineered heart tissue obtained by using human iPSC-derived from multipotential cardiovascular 
progenitors (MCP) implanted into a decellularized donor mouse heart [40]. In contrast to  
previous work that used donor cardiomyocytes, MCP—the earliest cardiac progenitors in heart 
development—gave rise to cardiomyocytes, smooth muscle cells and endothelial cells. The 
decellularized heart provided a 3D architecture and the complex natural extracellular matrix, which 
promoted cardiomyocyte proliferation, differentiation and myofilament formation. This use of native 
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cardiac scaffold also avoided the biocompatibility problems of some artificial scaffold materials. The 
resulting heart tissues presented the requisite features of rhythmic mechanical force generation, 
electrophysiological characteristics and response to drugs that make it a valuable model for the study 
of heart development and drug screening. Nevertheless, several improvements still have to be made to 
enable its use in regenerative medicine: heart fibroblasts are missing, since they do not derive from 
MCP and a functional cardiac conduction system has not been demonstrated. As a result, the 
mechanical force generated is insufficient and these model organs lack a coordinated electrical 
propagation necessary for synchronization of the tissues. 
2.2. Pancreas 
Although very much in the early stages of development as a complete tissue, functional islets of 
langerhans have also been created in vitro from iPSCs [41]. A protocol has been developed to 
differentiate iPSCs into glucose-responsive functional islets, with a 3D structure similar to adult 
pancreatic islets and that secreted insulin and improved blood glucose levels in hyperglycemic mice. 
The protocol involved a two-step cell culture method; first the differentiation of iPSCs to immature 
pancreatic cells and then second, culture in specific conditions that allow islet formation. The islets 
exhibited distinct 3D structural features similar to adult pancreatic islets and secreted insulin in 
response to glucose concentrations. Mice transplanted with the iPSC-derived islets normalized their 
blood glucose levels after nine days [41]. 
2.3. Brain 
Cerebral organoids have been made by culturing in a 3D system the neuroectoderm derived  
from human iPSC [42]. First, iPSCs were differentiated into embryoid bodies and from those 
neuroectoderm was derived. Neuroectodermal tissue was cultured in a 3D scaffold system of matrigel 
droplets and then transferred to a spinning bioreactor. The resulting three-dimensional tissue presented 
heterogeneous regions similar to human brain that were discrete but interdependent. These cerebral 
organoids, which the authors do not intend to use for regenerative purposes, recapitulated features of 
human cortical development. As mice and human brains have highly complex and integrated structures 
and developments, these organoids could be good candidates for the study of human brain 
development and modeling of brain disorders such as microencephaly. 
2.4. Liver 
A recent and exciting development in the field of bioengineering organs has been the creation of a 
liver bud which when transplanted into mice was able to rescue drug-induced liver failure [43]. In this 
case the researcher co-cultured iPSCs differentiated to hepatic endoderm with human mesenchymal 
stem cells and human umbilical endothelial cells. Co-cultured cells, when plated in a bi-dimensional 
matrigel layer self-organized into a three-dimensional system that the authors termed iPSC-derived 
liver buds. These liver buds were able to produce liver specific proteins such as albumin and were able 
to metabolize drugs ketoprofen and debrisoquine. Notably, the presence of human umbilical 
endothelial cells in the starting cell mixture provided the iPSC-derived liver buds with vessels that, 
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when implanted in the mice, connected with the host vessels within 48 h. This vascular system, 
together with the 3D structure seems to be the key for successful engraftment and maturation. 
2.5. Eye 
iPSCs have been used to generate optic vesicle-like structures that generated retinal cell types 
suitable for in vitro studies and disease modeling [44]. The authors differentiated iPSCs into 3D 
optical vesicles with the capacity of self-assemble into rudimentary neuroretinal structures and which 
expressed markers of intercellular communication. The use of retinal pigmented epithelial (RPE) cells 
to treat eye disease is currently being evaluated in clinical trials, leading the way for future research to 
develop the bio-engineered eye structures. 
2.6. Teeth 
The generation of complex tooth-like structures has been recently created from human iPSCs [45]. 
The authors developed a bioengineering protocol that combines iPSC-derived dental epithelial sheets 
with embryonic dental mesenchyme. The epithelial sheets gave raise to ameoblasts that produced the 
enamel component of the tooth and the embryonic dental mesenchyme produced the dentin-pulp 
complex and peridontium, as well as provided odontogenic signals to the epithelial sheets. The formed 
regenerative teeth were very similar in structure and mineral content to normal teeth and presented 
comparable hardness. As the sources of endogenous dental epithelial cells are scarce, iPSCs can 
provide a promising source of dental epithelial seed cells for use in tooth tissue engineering. 
2.7. Bone 
The bone tissue-engineering field has also made use of iPSC technology to create functional bone 
substitutes [46]. To make bone, iPSCs were differentiated into mesenchymal progenitors that were 
subsequently grown in an osteoconductive scaffold-perfusion bioreactor. The dense bone-like structure 
that formed inside the scaffold presented a mature bone molecular pattern. When implanted into mice, 
the engineered bone-tissue was stable over the 12 weeks of the study, without differentiation into other 
lineages, displayed vascular ingrowth and connective tissue development, and presented signs of 
initiation of scaffold resorption. 
2.8. Gut 
3D gut organoids have also been created from iPSC [47]. A protocol has been developed in which 
iPSCs were differentiated into intestinal tissue following a sequential protocol mimicking embryonic 
development. Spontaneous three-dimensional spheroids formed that were transferred to three-dimensional 
culture systems known to promote intestinal formation. The resulting intestinal tissue presented a 
cellular composition similar to that of foetal intestine and also presented absorptive and secretory 
functions. However these gut organoids have not been tested for engraftment and function in vivo.  
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3. Immune Response of iPSC Derived Cells 
As iPSC technology is advancing to become a future tool for clinical therapy, concerns about the 
susceptibility to immune rejection of iPSC grafts are increasing. As data accumulates, it has become 
apparent that iPSCs may not be as immune-privileged as initially thought [48]. Despite the sourcing of 
cells for iPSC treatment from the recipients, therefore overcoming HLA incompatibility, there remains 
the possibility that the reprogramming process itself might render the grafts or cells immunogenic [48]. 
Moreover, potential sources of innate proinflammatory “danger” signals that can lead to immune 
activation may be provided through the use of retroviral or episomal methods to make iPSC. 
Consistent with this, it has recently been demonstrated in mice that autologous transplantation of 
iPSCs, generated by episomal or retroviral vectors, elicited anti-graft T cell responses potent enough to 
prevent the formation of teratomas [49]. Interestingly, this was not observed with embryonic stem cells 
(ESC), where autologous transplantation in a syngeneic recipient did not elicit an immune response, 
suggesting the method to reprogram cells to the pluripotent state itself influences the ontogeny of 
immune responses within the host. Furthermore, the authors also found evidence of abnormal gene 
expression in some cells differentiated from iPSCs that were able to induce T-cell-dependent immune 
response in syngeneic recipients [49]. 
Recently, mouse iPSCs generated by lentivirus vectors or episomal vectors have been differentiated 
into representative cell types of the three germs layers and examined their immunogenicity in vitro and 
in vivo by transplantation into syngeneic recipients [50]. They found that differentiated cells derived 
from syngeneic iPSCs were not rejected after transplantation [50]. Moreover, model transplantation 
experiments were performed using various iPSC-derived differentiated tissues and immune-mediated 
rejections have not been observed. In further studies no differences in immunogenicity or transplantation 
success were found between differentiated skin and bone marrow tissue derived from integration-free 
mouse iPSCs (generated by episomal vectors) compared to that of ESC-derived tissue. This study  
did not observe any differences between the two groups in regards to the rate of transplantation  
success [51]. 
A very recent advance in this field has been a description of the induction of dopaminergic (DA) 
neurons from nonhuman primate iPSC by directed differentiation in vitro, and the comparison of the 
autologous and allogeneic transplantation into the brains of nonhuman primates [52]. Autologous 
transplantation of the iPSC-derived cells generated a minimal immune response compared with 
allografts in nonhuman primate brains in the absence of immunosupression. This data also entertains 
the idea that immunosupression is not necessary for autologous transplantation of iPSC-derived neural 
cells into brain. Moreover, they compared the immunogenicity of iPSCs generated with retroviral 
vectors versus episomal vectors. They detected that autologous grafts derived from iPSCs generated by 
retroviral vectors were infiltrated by a large number of IBA1
+
 and CD45
+
 microglia in comparison 
with those generated by episomal vectors, probably due to the residual expression of transgenes. This 
work suggests that residual transgenes can be immunogenic, for this reason it is crucial to use 
integration-free iPSCs [52]. 
Despite these recent advances, research to date has primarily focused on T cell mediated responses 
directed against stem grafts. However, many questions remain poorly understood, for example the role 
of NK cell mediated rejection in iPSC based transplantation technology. This seems to be especially of 
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interest as the HLA class I and II expression on ESCs has been shown to vary depending on their 
maturation status [53]. Although a low expression of HLA has been thought to partially explain the 
reduced immunogenicity of ESCs, this reduced expression of HLA may in turn render these cells more 
vulnerable to NK cell mediated killing. 
In summary, there is now encouraging evidence that grafts from terminally differentiated cells 
derived from syngeneic iPSCs can circumvent acute rejection in animal models. However, these 
studies also highlight the “devil in the detail” and show that even subtle differences in the generation 
of iPSCs may render them more or less immunogenic. Consequently, the future of the study of 
immunity against iPSCs is complicated by the simple truth that iPSCs are dynamic antigenic targets 
and that the immune response elicited by those cells will likely differ based on their generation, 
differentiation, age, and survival in vivo. 
4. Conclusions 
Both methods of direct reprogramming to desired cells types or full reprogramming to iPSCs and 
then differentiating to cells for replacement therapy have pros and cons for future clinical application. 
The length of time required for generation and differentiation of iPSCs into the desired cell type is the 
main handicap of iPSCs in comparison to directly reprogrammed cells. In addition differentiation  
of iPSCs to some cell types have not been achieved, for example, blood and functional sperm, with 
cells remaining in undifferentiated embryological cell states. Moreover, direct reprogramming avoids 
going through the big hurdle of the transient tumorigenic state of iPSCs. For this reason, direct 
reprogrammed cells could be a better choice in the clinical application for human cell replacement 
therapy for neurodegenerative disorders like Parkinson’s disease, Huntington’s disease, and amyotrophic 
lateral sclerosis. 
However, directly reprogrammed cells are also susceptible to chromosomal aberrations [54,55] and 
all methods for direct reprogramming of cells to date have used viral transduction methods to insert 
genes into the genome of cells. Another con for direct reprogramming is that some cells have been 
shown to maintain an epigenetic memory of their cell of origin, like neurons, questioning their stability 
over time [56]. Moreover, with direct reprogramming the intermediate cell steps that form during the 
process are difficult to identify because the molecular markers they express remain unknown [1]. 
Therefore, iPSCs may be the cell choice for future regenerative medicine applications, given that  
they are well defined, characterized, and that their proliferative capacity is an advantage over post 
mitotically inactive direct reprogrammed cells. 
Perhaps one of the major advantages of iPSCs will be for engineering of human organs for 
transplantation. The co-culturing of more than one cell type has proven successful for making a 
functional liver bud and although iPSCs were used in this study not all the cells used in the mix were 
derived from iPSCs [43]. Combining two or more cell types all derived from iPSCs to make complex 
organs like the liver, brain or heart may be needed in the near future. If this is possible, the powerful 
ability to efficiently produce pluripotent cells to seed the growth of autologous body organs for 
transplant medicine may be achievable in the near future.  
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